Preoperative combination chemotherapy improved survival in pancreatic cancer

FDA approves pancreatic cancer device

FDA approved a first-of-its-kind device for the treatment of adult patients with locally advanced pancreatic cancer. Optune Pax, developed by Novocure, is a portable, non-invasive device that delivers alternating electrical fields, known as tumor treating fields, to the abdomen.

February 20, 2026

Vol.52 No.07

In Brief

“The Journey to End Cancer: From Cause to Cure” exhibit launches national tour, with MD Anderson as presenting sponsor

The University of Texas MD Anderson Cancer Center is launching a science exhibition, showcasing the research, technologies, and new therapies bringing progress in the mission to end cancer.

February 13, 2026

Vol.52 No.06

Clinical Roundup

Immunity against CMV leveraged against pancreatic cancer in study by UCSD, La Jolla Institute of Immunology

Researchers at the University of California San Diego and La Jolla Institute of Immunology have discovered a promising treatment approach for pancreatic cancer, one of the deadliest and most treatment-resistant forms of cancer. The approach leverages the body’s natural immune response to cytomegalovirus, a common but typically harmless virus that most people are infected with at some point in their lives.

February 13, 2026

Vol.52 No.06

Clinical Roundup

Mutation predicts chemoresistance and better responses to immunotherapy in advanced bladder cancer, MD Anderson study finds

Researchers at The University of Texas MD Anderson Cancer Center have determined that mutations in the KDM6A gene—common in advanced bladder cancer—may serve as a predictive biomarker to determine which patients are less likely to benefit from standard chemotherapy but may respond better to immunotherapy.

January 16, 2026

Vol.52 No.02

Drugs & Targets

SOPHiA GENETICS partners with MD Anderson on AI-driven precision oncology

SOPHiA GENETICS and The University of Texas MD Anderson Cancer Center have entered into a collaboration to accelerate data-driven cancer care through new tools that can accurately analyze, interpret, and translate diagnostic results into clinical practice.

January 09, 2026

Vol.52 No.1

Clinical Roundup

Proton vs. traditional radiation therapy significantly improves survival in head and neck cancers, MD Anderson-led study finds

Patients with oropharyngeal cancers who were treated with proton therapy, compared to traditional radiation therapy saw a significant survival benefit, according to the findings from a phase III trial led by researchers at the University of Texas MD Anderson Cancer Center.

December 19, 2025

Vol.51 No.46

Preoperative combination chemotherapy improved survival in pancreatic cancer

YOU MAY BE INTERESTED IN

FDA approves pancreatic cancer device

“The Journey to End Cancer: From Cause to Cure” exhibit launches national tour, with MD Anderson as presenting sponsor

Immunity against CMV leveraged against pancreatic cancer in study by UCSD, La Jolla Institute of Immunology

Mutation predicts chemoresistance and better responses to immunotherapy in advanced bladder cancer, MD Anderson study finds

SOPHiA GENETICS partners with MD Anderson on AI-driven precision oncology

Proton vs. traditional radiation therapy significantly improves survival in head and neck cancers, MD Anderson-led study finds

Renew today!

Subscriber content

Never miss an issue!

Login